Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often lack precision, leading to damage of healthy tissues surrounding the tumor and limiting the effectiveness of immune therapies. Targeted drug delivery methods are needed to improve treatment efficacy and reduce side effects.
Solution
Sonokine Bioscience is developing a cancer treatment platform that combines ultrasound technology with targeted delivery of immune therapies. Their approach uses focused ultrasound to enhance the precision of drug delivery directly to the tumor microenvironment, stimulating a localized immune response. By precisely targeting the tumor, Sonokine aims to minimize damage to surrounding healthy tissues, improve the therapeutic index of immune therapies, and enhance the overall effectiveness of cancer treatment.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking more precise and effective cancer treatment options, as well as pharmaceutical companies developing novel immune therapies.
Features
- Focused ultrasound technology for targeted drug delivery
- Enhanced precision in delivering immune therapies to the tumor microenvironment
- Minimized damage to surrounding healthy tissues
- Improved therapeutic index of cancer treatments